Demographic of study subjects
| Number of subjects | OAC-treated group (n=102) | Placebo group (n=100) |
| Inflammation at baseline | 102 | 100 |
| Inflammation at after 1 year | 16 | 91 |
| Atrophy at baseline | 17 | 15 |
| Atrophy after 1 year | 37 | 40 |
| Intestinal metaplasia at baseline | 49 | 45 |
| Intestinal metaplasia after 1 year | 24 | 29 |
OAC, omeprazole, amoxicillin and clarithromycin.